Competing interests: J.R. reports clinical research grants from Amgen, Applied Therapeutics, AstraZeneca, Biomea Fusion, Boehringer Ingelheim, Corcept, Corxel, Eli Lilly, Hanmi, Merck, Novo Nordisk, Pfizer, Regeneron, Roche, Regor, Sanofi, Structure Therapeutics and Terns; J.R. serves or has served on scientific advisory boards and received honorarium or consulting fees from Amgen, Applied Therapeutics, Arrowhead, Biomea Fusion, Boehringer Ingelheim, Corcept, Eccogene, Eli Lilly, Hanmi, i2O Therapeutics, Novo Nordisk, Regeneron, Roche, Sanofi, Structure Therapeutics and Terns, and has received honoraria for lectures from Eli Lilly, Novo Nordisk and Sanofi. I.L. reports received research funding (paid to institution) and/or product from NovoNordisk, Boehringer-Ingelheim, Dexcom, Roche, Pfizer and Lilly; research related consulting fees (paid to institution) from NovoNordisk; advisory or consulting fees and/or other support from Aadvarak Therapeutics, Abbvie, Adarx, Altasciences, Alveus Therapeutics, Amgen, Antag Therapeutics, Arrowhead Pharmaceuticals, Astra Zeneca, Baim Institute, Bain Capital, Bayer, Betagenon, Bioio, Biomea, Boehringer-Ingelheim, Boston Scientific, Carmot, Corxel, Cytoki Pharma, Eli Lilly, Genentech, Janssen/J&J, Juvena, Kailera Therapeutics, Keros Therapeutic, Mediflix, Metsera, Neurocrine, Novo Nordisk, Penguin Bio, Pfizer, Regeneron, Response Pharmaceutical, Roche, Sanofi, Shionogi, Sparrow, Skye Bioscience, Source Bio, Structure Therapeutics, SUMMIT, Tenvie, TERNS Pharma, Verdiva Bio, Viking Therapeutics and Zealand Pharma. D.R. reports having received consulting honoraria from Abbvie, Altimmune; Amgen, AstraZeneca, Biohaven, Boehringer Ingelheim, Calibrate, Carmot Therapeutics, Currax Pharmaceuticals, CinRx, Eli Lilly, Epitomee, Fractyl Health, i2o, ICON, Kailera, Novo Nordisk, Pfizer, PPD, Protagonist, Regor, Rhythm, Souffle, Source Bio, Structure Therapeutics, Tenvie, Viking Therapeutics, WondrHealth, Weight Watchers and Zealand Pharma. She has received stock options from Calibrate, Epitomee and Ro Health. A.M.J. conducts multicenter trials with Amgen, Boehringer Ingelheim, Eli Lilly, Novo Nordisk and Rhythm Pharmaceuticals and serves on scientific advisory boards for Amgen, AstraZeneca, Boehringer Ingelheim, Biohaven, Eli Lilly, i2o, Intellihealth/Flyte, Metsera, Novo Nordisk, Pfizer, Regeneron, Roche/Genentech, Scholar Rock, Structure Therapeutics, Syntis Bio, Viking, Wave, WW International and Zealand Pharmaceuticals; academic cofounder State 4 Therapeutics. R.K. reports a position of a medical board member, advisor or consultant for Abbvie, Antag, AstraZenica, Boehringer Ingelheim, Currax, Eli Lilly, Novo Nordisk, Structure, Viking and Weight Watchers. A.A. reports participation on an advisory board or data monitoring board for Amgen, Boehringer Ingelheim, Currax, Structure Therapeutics and Regeneron; grant support to the institution from Vivus, Novo Nordisk, Phenomix Sciences and Terns Pharmaceutical; and consulting fees to the institution from Amgen, RareStone and Bausch Health. T.C.B. reports speaker or advisory relationships with BI, Eli Lily, Mannkind, and Sanfi and research funding from BI, Amgen, Dreamed, Sanofi, AstraZeneca, Eli Lily, Novo Nordisk, Sequel, Insulet, Structure, vTv, Medtronic, and Tandem Diabetes Care. M.C. reports no competing interests. F.L.H. reports no competing interests. T.S. is a primary investigator of studies sponsored by Lilly, Amgen, Novo Nordisk, Novartis, Boehringer Ingelheim, AbbVie, Reata and Vertex. L.C. reports clinical investigator activity for Eli Lilly and Structure Therapeutics. Y.L., M.L., A.B., J.B., A.C., H.Y. and B.C. are employees of Structure Therapeutics and report no other competing interests.
PubMed
GLP-1 Therapies